Irinotecan and topotecan are camptothecin derivatives routinely used to treat ovarian, colon and lung cancers as well as hematologic and pediatric malignancies. However, camptothecins have well-defined limitations including chemical instability (due to their alpha-hydroxylactone structure), drug efflux by the ABCG2 and ABCB1 plasma membrane transporters, and dose-limiting gastro-intestinal and bone marrow toxicity. We are pursuing the discovery and molecular pharmacology of novel Top1-targeted anticancer agents to alleviate these limitations. We have discovered the indenoisoquinolines, patented and pursued them in collaboration with Dr. Cushman at Purdue University and the NCI Drug Development Program (DTP). The indenoisoquinolines have several advantages over camptothecins: 1/ they are chemically stable and easy to synthesize and chemically optimize;2/ they trap Top1 cleavage complexes at specific genomic sites that differ from those trapped by camptothecins;3/ their cellular half-life is much longer than camptothecins;4/ the Top1 cleavage complexes they produce are more stable than those trapped by camptothecins indicating a tight fit in the Top1-DNA cleavage complexes;5/ they are not substrates for the multidrug resistance efflux pumps (such as ABCB1 (Pgp), ABCG2 (Mrp/Bcrp) and ABCC1 (Mrp1). Two indenoisoquinolines (NSC 725776, LMP776 -- indimitecan and 743400, LMP400--indotecan) are in human clinical trials at the NCI. and three indenoisoquinolines (LMP776, LMP400 and NSC 706744) are in dog clinical trials (CCR Comparative Oncology Program, COP). This drug development is a collaboration between LMP (our group and Dr. Bonner for gamma-H2AX biomarker), the Clinical Oncology Branch (Dr. Doroshow and Shivaani Kummar for clinical trials), the CCR-COP (Dr. Chand Khanna), DTP and SAIC (Dr. Hollingshead, Dr. Parchment and Dr. Kinders for mouse models and pharmacodynamic biomarkers), and Purdue University (Dr. Mark Cushman for drug synthesis). Our goal is to make the indenoisoquinolines the first NCI-discovered drugs in the Phase 0/I pipeline with histone gamma-H2AX as a biomarker. We have also completed the molecular pharmacology of another non-camptothecin Top1 inhibitor (Genz-644282), which is completing Phase I clinical trial. We have published the molecular and cellular pharmacology of Genz-644282 and its metabolites, showing the value of histone gamma-H2AX as a biomarker for Genz-644282. This research exemplifies one aspect of our translational research aimed to discover and develop new drugs, to generate pharmacodynamic biomarkers and to work as a team both with the NCI drug development program and the pharmaceutical industry under clearly defined research agreements (referred to as CRADA). Regarding the basic biology of topoisomerases, we have shown (Kim et al. Science 2011) that, when Top1 binds to a DNA substrate with a misincorporated ribonucleotide, the Top1cc is spontaneously converted into a single-strand break after the 2-prime-hydroxyl group of the sugar eliminate Top1 by forming a 2-prime,3-prime-cyclic nucleotide at the 3-prime-end of the break that was initially made by Top1. This finding is important for two reasons: first, because Thomas Kunkel and his group, one of our collaborators, have recently shown that ribonucleotides are readily misincorporated during normal replication, and second because those misincorporation sites give rise to short nucleotide deletions and insertion in a Top1-dependent manner. Together these new results add to our previous findings showing the recombinogenic and potentially mutagenic properties of Top1. We have also initiated a new set of studies that relate Top1 to transcription and published three manuscripts on these topics within the past year. First, we reveal the critical relationship between Top1 and transcription stop points that are associated with the formation of alternative DNA structures (guanosine quartets and R-loops) in the negatively supercoiled DNA segments that tend to arise in the wake of transcription complexes. Such negative supercoiling is facilitated by deficiency in Top1, which under normal conditions functions to eliminate the negative supercoiling generated in the wake of moving transcription complexes. We also demonstrated that Top1 stabilization by Top1-targeted drugs (and abnormal DNA structures;see above) induces abnormal splicing, especially in genes that encode splicing factors. Mitochondrial type IB topoisomerase, Top1mt, was discovered in our laboratory. Top1mt is encoded by a nuclear gene present in all vertebrates. We have proposed that Top1mt arose by duplication of a common ancestral TOP1 gene (found today in simple chordates and more distantly in yeast and plants). The other TOP1 gene encodes the previously known Top1 devoted to the nuclear genome. We have generated specific antibodies for Top1mt, which enabled us to demonstrate that Top1mt is absent from nuclei and concentrated in mitochondria. We have also found that Top1mt can be trapped by camptothecin and used this finding to map the Top1mt binding sites in mitochondrial DNA (mtDNA). Mapping of Top1mt sites in the regulatory D-loop region of mtDNA in mitochondria revealed the presence of an asymmetric cluster of Top1mt sites confined to a 150-bp segment downstream from, and adjacent to, the site at which replication is prematurely terminated, generating a 650-base (7S DNA) product that forms the mitochondrial D-loop. Moreover, we showed that inhibition of Top1mt by camptothecin reduces formation of the 7S DNA. Our results suggest novel roles for Top1mt in regulating mtDNA replication. We have also generated Top1mt knockout mice. Unexpectedly, the Top1mt knockout mice are viable and fertile. We recently reported that MEFs generated from those mice have defective mitochondrial functions with enhanced production of oxygen radicals (ROS) and metabolic reprogramming toward glycolytic and lipolytic pathways (Warburg effect). We have also shown that the TOP1mt gene is correlated with the other mitochondrial genes and under the control of c-MYC. We are currently analyzing the mitochondrial DNA and mitochondrial functions in TOP1mt knockout cells and mice. Because of the viability of the Top1mt knockout mice, we are actively looking for other topoisomerase that can complement Top1mt in mitochondria and at the phenotype of cells without Top1mt or with a toxic Top1mt.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIABC006161-30
Application #
8763008
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
30
Fiscal Year
2013
Total Cost
$932,263
Indirect Cost
Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
Zip Code
Beck, Daniel E; Agama, Keli; Marchand, Christophe et al. (2014) Synthesis and biological evaluation of new carbohydrate-substituted indenoisoquinoline topoisomerase I inhibitors and improved syntheses of the experimental anticancer agents indotecan (LMP400) and indimitecan (LMP776). J Med Chem 57:1495-512
Murai, Junko; Marchand, Christophe; Shahane, Sampada A et al. (2014) Identification of novel PARP inhibitors using a cell-based TDP1 inhibitory assay in a quantitative high-throughput screening platform. DNA Repair (Amst) 21:177-82
Dalla Rosa, Ilaria; Huang, Shar-Yin N; Agama, Keli et al. (2014) Mapping topoisomerase sites in mitochondrial DNA with a poisonous mitochondrial topoisomerase I (Top1mt). J Biol Chem 289:18595-602
Gao, Rui; Schellenberg, Matthew J; Huang, Shar-Yin N et al. (2014) Proteolytic degradation of topoisomerase II (Top2) enables the processing of Top2┬ĚDNA and Top2┬ĚRNA covalent complexes by tyrosyl-DNA-phosphodiesterase 2 (TDP2). J Biol Chem 289:17960-9
Gao, Rui; Das, Benu Brata; Chatterjee, Raghunath et al. (2014) Epigenetic and genetic inactivation of tyrosyl-DNA-phosphodiesterase 1 (TDP1) in human lung cancer cells from the NCI-60 panel. DNA Repair (Amst) 13:1-9
Zhang, Hongliang; Zhang, Yong-Wei; Yasukawa, Takehiro et al. (2014) Increased negative supercoiling of mtDNA in TOP1mt knockout mice and presence of topoisomerases II? and II? in vertebrate mitochondria. Nucleic Acids Res 42:7259-67
Kiselev, Evgeny; Sooryakumar, Dhriti; Agama, Keli et al. (2014) Optimization of the lactam side chain of 7-azaindenoisoquinoline topoisomerase I inhibitors and mechanism of action studies in cancer cells. J Med Chem 57:1289-98
Lv, Peng-Cheng; Agama, Keli; Marchand, Christophe et al. (2014) Design, synthesis, and biological evaluation of O-2-modified indenoisoquinolines as dual topoisomerase I-tyrosyl-DNA phosphodiesterase I inhibitors. J Med Chem 57:4324-36
Khiati, Salim; Dalla Rosa, Ilaria; Sourbier, Carole et al. (2014) Mitochondrial topoisomerase I (top1mt) is a novel limiting factor of doxorubicin cardiotoxicity. Clin Cancer Res 20:4873-81
Pommier, Yves (2009) DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition. Chem Rev 109:2894-902

Showing the most recent 10 out of 23 publications